. intolerance). Ibrutinib is The existing gold standard therapy for clients with relapsed/refractory ailment, based on the outcome of a number of phase I-III trials, one hundred fifteen–119 but this is also modifying for two key reasons: (i) a growing proportion of individuals at present receive ibrutinib as frontline therapy; and (ii) a number o